Headlines Expert Newsletters Covid-19 Specialties Trending Feeds Videos

5005 Background: Both TITAN and ARCHES studies have demonstrated significant clinical benefits of second-generation androgen receptor inhibitors (ARIs) plus ADT versus placebo plus ADT in the treatment of mHSPC. However, first-generation ARIs plus ADT is also widely used in clinic and how superior second-generation ARIs is to first-generation ones remains to be determined. Here, we evaluated the...

  • 123456 Profile photo of Madelyn

    More in doublet therapy for mHSPC….potentially a new treatment option. Authors reported they are submitting to FDA so will see if this gets approved.